Asterias Biotherapeutics Inc

Asterias Biotherapeutics — Investor Day (May 2015)

17 slides from Asterias Biotherapeutics's investor day presentation, May 8, 2015

  1. Slide 1: Design, Objectives, and Status of Asterias' Current Spinal Cord Injury Clinical Trial

    Design, Objectives, and Status ofAsterias’ Current Spinal Cord InjuryClinical Trial Edward Wirth, III, M.D., Ph.D. Chief Medical Officer Investor DayMay 8, 2015 *

  2. Slide 2: AST-OPC1: Phase 1 Safety Study in Complete Thoracic SCI

    AST-OPC1: Phase 1 Safety Study in Complete Thoracic SCI * MRI MRI MRI MRI MRI MRI MRI MRI MRI MRI Primary Assessment: SafetySecondary Assessment: ISNCSCI examsExploratory AssessmentsUAB-IMRSCIMSCI Pain Basic Data SetBowel and Bladder Basic Data Set Open Label TrialMulti-Center (7 sites)8-10 Subjects

  3. Slide 3: AST-OPC1: Subject Demographics

    AST-OPC1: Subject Demographics Demographic and Baseline Disease Characteristics – All Treated Subjects Demographic and Baseline Disease Characteristics – All Treated Subjects Demographic and Baseline Disease Characteristics – All Treated Subjects Demographic and Baseline Disease Characteristics – Al

  4. Slide 4: Delivery of AST-OPC1 in Complete Thoracic SCI Was Feasible and Safe

    Delivery of AST-OPC1 in Complete Thoracic SCI Was Feasible and Safe * All Subjects Received AST-OPC1 (2 x 106 cells) at 1-2 weeks of post-injuryInjections performed using a Syringe Positioning Device (SPD)No intraoperative complicationsNo SAEs Associated with Delivery of Cells9 Adverse Events Possib

  5. Slide 5: Immunosuppression Regimen Was Well-Tolerated

    Immunosuppression Regimen Was Well-Tolerated All Subjects Completed Tacrolimus Immunosuppression RegimenNo SAE’s Associated with Immunosuppression16 Grade 1 or 2 Adverse Events Possibly Associated with ImmunosuppressionNausea, Urinary Tract Infection, Low Magnesium Blood Levels *

  6. Slide 6: No Evidence of AST-OPC1 Directed Immune Responses One Year After Administration

    No Evidence of AST-OPC1 Directed Immune Responses One Year After Administration Immune monitoring shows no evidence of antibodies or cellular immune responses to AST-OPC1 through 1 year in all subjects Some subjects complete mismatch with AST-OPC1: Closest match was 5 of 10 alleles PRA Assay ELISpot

  7. Slide 7: AST-OPC1 Was Well Tolerated

    AST-OPC1 Was Well Tolerated No SAE’s Associated with AST-OPC1No Evidence of adverse findings on MRI scans5 Adverse Events Possibly Associated with AST-OPC1Transient Low Grade Fever (1)Burning Sensation in Trunk and Lower Extremities (4 in one subject) Subject SAE Timeframe Related to AST-OPC1 1101 P

  8. Slide 8: No Major Sensory Neurological Changes Observed

    No Major Sensory Neurological Changes Observed Neurological Level Neurological Level Zone of Partial Preservation Zone of Partial Preservation Subject Visit Right Side Sensory Left Side Sensory Right Side Sensory Left Side Sensory 1002 Baseline T6 T6 T7 T7 Year 1 T6 T7 T7 T7 Year 2 T6 T6 T7 T7 Year

  9. Slide 9: MRI Results: Evidence Consistent with Prevention of Lesion Cavity Formation

    MRI Results: Evidence Consistent with Prevention of Lesion Cavity Formation No adverse findings on primary MRI safety readsIn 4 of 5 subjects, graft sites are hyperintense on T2, but signal intensity is < CSFSuggests lesion cavity formation may have been prevented by formation of a tissue matrix Ima

  10. Slide 10: Summary of Findings from First in Man Study of AST-OPC1

    Summary of Findings from First in Man Study of AST-OPC1 AST-OPC1 is extremely well tolerated, with no SAEs to date deemed related to the cells, delivery method, or immunosuppressive regimen4 of 5 patients have completed 3 year follow up visit, one has completed 4 years of follow-up5th patient will c

  11. Slide 11: AST-OPC1: Scientific Rationale for Evaluation in Cervical SCI Patients

    AST-OPC1: Scientific Rationale for Evaluation in Cervical SCI Patients Repair/regeneration of axons only required over a short distance to reinnervate motor neurons for arms & handsFor example, with an SCI at C6 (last intact motor level at C5), repair of axons to C7 could yield return of 2 motor lev

  12. Slide 12: AST-OPC1: Medical Rationale for Evaluation in Cervical SCI Patients

    AST-OPC1: Medical Rationale for Evaluation in Cervical SCI Patients Few complete cervical SCI patients recover >= 2 motor levels with current standard of careRecovery of >= 2 motor levels leads to significant improvement in self-care abilitySelf-care ability could be a clinically meaningful endpoint

  13. Slide 13: Design of Phase 1/2a Study of AST-OPC1 in Complete Cervical SCI

    Design of Phase 1/2a Study of AST-OPC1 in Complete Cervical SCI 6m efficacy data 10M cell cohort (N=5) 20M cell cohort (N=5) 2M cell cohort (N=3) Key Design ElementsAST-OPC1 Injection 14-30 days post-injury10 day stagger within cohortsDMC review prior to dose escalation Efficacy TargetRecovery of >=

  14. Slide 14: AST-OPC1 Phase 1/2a Study Schema

    AST-OPC1 Phase 1/2a Study Schema * Acute completecervical SCI Protocol AST-OPC1-01 Protocol AST-OPC1-02 Day 0 Day 7 Day 30 Day 60 Day 90 Day 180 1 Year 5 Years 15 Years In personvisits Phone f/u DiscontinueImmunosuppression Days 46-60ImmunosuppressionTaper AST-OPC1Injection14-30 DaysPost-SCI Day -1

  15. Slide 15: Operational Update

    Operational Update First two clinical sites are open for enrollment (Shepherd Center, Atlanta; Rush University, Chicago)Third clinical site expected to open in May (Stanford/Santa Clara Valley Medical Center)Patient recruitment efforts initiatedStudy website landing page to go live in MayBranding an

  16. Slide 16: AST-OPC1 Phase 1/2a Trial: Design and Milestones

    AST-OPC1 Phase 1/2a Trial: Design and Milestones * Cohort 1:3 subjects2 million cells Cohort 2:5 subjects10 million cells Cohort 3:5 subjects20 million cells Q1’15: Study initiates Q3’15: Dose escalation Q1’16: Dose escalation 1H’16: 6 mo efficacy, cohort 2

  17. Slide 17: > CASI S

    \. > CASI S yg A.

Asterias Biotherapeutics — Investor Day (May 2015) on 6ix